Eosinophil depletion by anti–Siglec-F reverses arterial thrombosis and reduces EETs and NETs in 10 weeks WTD-fed Lnk^−/−Ldlr^−/− recipient mice. (A) Eosinophil, neutrophil, and platelet counts in Ldlr^−/− and Lnk^−/−Ldlr^−/− recipient mice treated with isotype control antibody or anti–Siglec-F antibody (20 μg per mice, 24 hours, IV injection). (B) FeCl₃-induced carotid artery occlusion in Ldlr^−/− and Lnk^−/−Ldlr^−/− recipient mice treated with isotype control antibody or anti–Siglec-F antibody. (C) Representative images of Fibrinogen (red) staining and EETs staining in carotid artery thrombi of WT and Lnk^−/− treated with isotype control antibody or anti–Siglec-F antibody. EETs were quantified using MBP (green) with H3Cit (red); n = 5 per group. (D) Representative images and quantifications of NETs using MPO (green) with H3Cit (red) in thrombi of Ldlr^−/− and Lnk^−/−Ldlr^−/− recipient mice treated with isotype control antibody or anti–Siglec-F antibody (n = 5-6 per group). (E) Quantification of eosinophil number (MBP⁺CD11b⁺) and neutrophil number (MPO⁺DAPI⁺) per thrombi. Scale bar, 100 μm.